Guangji Pharmaceutical announced that revenue for the first half of 2026 was 312 million yuan, up 9.71% year on year; net profit loss attributable to shareholders of listed companies was 579.451 million yuan, loss of 75.551 million yuan for the same period in 2025; net profit loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 65.5887 million yuan, and loss of 784.109 million yuan for the same period in 2025. The company plans not to pay cash dividends, bonus shares, or use the Provident Fund to increase share capital.

Guangji Pharmaceutical announced that revenue for the first half of 2026 was 312 million yuan, up 9.71% year on year; net profit loss attributable to shareholders of listed companies was 579.451 million yuan, loss of 75.551 million yuan for the same period in 2025; net profit loss attributable to shareholders of listed companies after deducting non-recurring profit and loss was 65.5887 million yuan, and loss of 784.109 million yuan for the same period in 2025. The company plans not to pay cash dividends, bonus shares, or use the Provident Fund to increase share capital.